Joshua Richter

43PUBLICATIONS
127CO-AUTHORS
Nuclear physicsGene and molecular therapyApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Cancer therapy (excl. chemotherapy and radiation therapy)Predictive and prognostic markers
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (43)

|Jul 22, 2026
International Myeloma Working Group Recommendations for the Diagnosis and Management of Solitary Plasmacytomas.

|Jul 14, 2026
Effectiveness of daratumumab plus bortezomib, lenalidomide, and dexamethasone (DVRd) versus VRd for transplant-eligible newly diagnosed multiple myeloma.

|Jul 10, 2026
Linvoseltamab versus elranatamab for triple-class exposed relapsed or refractory multiple myeloma: an indirect treatment comparison.

|Jul 08, 2026
Belantamab mafodotin, a BCMA-directed antibody-drug conjugate for multiple myeloma.

|Jun 25, 2026
A systematic review of indirect treatment comparisons among recently approved chimeric antigen receptor T-cell and bispecific antibody therapies for triple-class exposed relapsed/refractory multiple myeloma.

|Jun 13, 2026
Comparative Efficacy of Belantamab Mafodotin in Combination With Bortezomib and Dexamethasone Versus Standards of Care in Patients With Third-Line or Later Relapsed/Refractory Multiple Myeloma.

Pageof 8

Frequent Collaborators

12 joint publications

Hearn Jay Cho

11 joint publications

Sundar Jagannath

8 joint publications

Santiago Thibaud

7 joint publications

Shambavi Richard